Wells Fargo lowered the firm’s price target on Danaher (DHR) to $205 from $210 and keeps an Equal Weight rating on the shares. The firm notes the company posted a solid beat/raise on EPS, while also leaving another about +15c-20c in its back pocket. Bioprocess continues to show a solid recovery, while LS should improve in the second half of the year. Pharma and China commentary was positive, Wells adds, arguing that CFO transition seems manageable.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DHR:
- Balanced Outlook for Danaher: Solid Earnings Beat Amidst Cautious Guidance and Mixed Segment Performance
- Danaher: Strong Q2 Performance and Growth Potential Justify Buy Rating
- Danaher Corporation Reports Steady Q2 2025 Earnings
- Danaher Earnings Call: Balancing Growth and Challenges
- Danaher’s Growth Potential and Strategic Positioning Justify Buy Rating